Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435184 · ClinicalTrials.gov registry record · Phase 2
Crizanlizumab for Treating COVID-19 Vasculopathy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04435184: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT04435184 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04435184, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.
Interventions
- DRUG Crizanlizumab
- OTHER 0.9% saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2021-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04435184
The ClinicalTrials.gov registry entry for NCT04435184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Crizanlizumab is the first listed.
NCT04435184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04435184 about?
NCT04435184 is a clinical study titled "Crizanlizumab for Treating COVID-19 Vasculopathy". The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.
What is the current status of trial NCT04435184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-07-09. Estimated completion is 2021-01-04.
What interventions are being tested in trial NCT04435184?
The interventions under investigation include: Crizanlizumab (DRUG), 0.9% saline (OTHER).
Who is sponsoring clinical trial NCT04435184?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.